Ask Warren

Shinil Pharmaceutical

012790 · KOSDAQ · ₩012790 · 신일제약

₩6,090▼ ₩180 (2.87%)End-of-day · Oct 30, 2026 · End-of-day prices.
Trade
Alert me
SellBuy
AnnualQuarterly

Income statement

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Revenue₩24B₩21B₩21B₩21B₩20B₩19B₩22B₩21B
Cost of sales₩13B₩11B₩14B₩12B₩10B₩11B₩11B₩12B
Gross profit₩11B₩10B₩7.2B₩8.8B₩9.2B₩8.2B₩10B₩9.1B
Operating income₩2.3B₩1.3B−₩424M₩2.7B₩3.2B₩2B₩4B₩3B
Net income₩806M₩1.4B₩133M₩2.6B₩2.8B₩2B₩3.9B₩2.8B
Net income to shareholders₩806M₩1.4B₩133M₩2.6B₩2.8B₩2B₩3.9B₩2.8B

Balance sheet

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Total assets₩175B₩172B₩169B₩170B₩167B₩167B₩166B₩160B
Current assets₩89B₩85B₩83B₩83B₩78B₩78B₩77B₩73B
Cash and equivalents₩10B₩8.3B₩9.3B₩8.5B₩6B₩6.5B₩4.6B₩6.6B
Total liabilities₩21B₩18B₩17B₩18B₩18B₩21B₩19B₩17B
Current liabilities₩18B₩15B₩15B₩15B₩14B₩17B₩16B₩15B
Borrowings₩1.1B———————
Total equity₩154B₩154B₩152B₩152B₩149B₩146B₩147B₩143B
Shareholders' equity₩154B₩154B₩152B₩152B₩149B₩146B₩147B₩143B

Cash flow

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Cash from operations₩5.4B₩1B₩1.9B₩2.6B₩3.9B₩3.2B₩3.6B₩4.6B
Capital spending₩542M₩2B₩170M————₩2.5B
Free cash flow₩4.8B−₩950M₩1.7B₩2.6B₩3.9B₩3.2B₩3.6B₩2.1B
Dividends paid——₩0₩0₩0₩2.2B₩0₩0

Consolidated where available. Amounts in won.

Also known as: Shinil Pharmaceutical / 신일제약 / 012790 / KRX:012790

Source: KRX statistical information